First look: some small signs of improvement sequentially and year-on-year at RXO
Revenue was $1.41 billion compared to $930 million a year ago. Sequentially, when the comparison is on an equal basis reflecting the Coyote business, revenue at RXO was down slightly from $1.43 billion in the first quarter.
More significant of RXO's financial position on a year-on-year basis was the company's gross margin of 17.8% in the second quarter, compared to 19% a year earlier. The second quarter gross margin in 2025 was identical to that of 2025's first quarter.
RXO said its brokerage volume growth was up 1% year-over year. Full truckload volume was down 12% year-on-year. But the company's less than truckload volume took a big jump of 45% compared to the second quarter of 2024.
The truck brokerage margin at RXO was improved sequentially at 14.4%, compared to 13.3% in the first quarter. But it was down from 14.7% a year earlier.
RXO in both the second quarter of 2024 and 2025 was essentially a breakeven company on an operating basis. The net loss on a GAAP basis was $9 million in 2025's second quarter and $7 million a year earlier.
Adjusted net income in the quarter, a non-GAAP measure, was a positive $7 million, compared to adjusted net income of $4 million in the second quarter of 2024.
The breakeven operating income in 2Q 2025 was an improvement over the $30 million operating loss posted in the first quarter. The net loss per share was minus 5 cents in the second quarter of 2025, minus 6 cents a year earlier and minus 18 cents in the first quarter of 2024.
Adjusted EBITDA in the second quarter was $38 million, rising from $28 million in the second quarter of 2024. That line item was $22 million in the first quarter.
In the prepared statement released with the earnings, RXO CEO Drew Wilkerson said the company 'executed well in the second quarter despite the prolonged soft freight market.' Besides citing the growth in brokerage volume, he said the company's Last Mile has 'continued its impressive run of year-over-year growth, achieving 17% stop growth.'
'We're focused on growing profitably, and we're realizing the benefits of our increased scale,' he said in the statement. 'That scale, combined with our cutting-edge technology, is driving productivity improvements.'
More articles by John Kingston
Averitt pay increase could be a sign of some acceleration in driver wages
At C.H. Robinson, improved profitability, productivity and a lot fewer workers
Each driver's payout in Lytx Illinois biometrics case will be between about $650 and $850
The post First look: some small signs of improvement sequentially and year-on-year at RXO appeared first on FreightWaves.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Medical Devices & Supplies - Specialty company Inspire Medical Systems (NYSE:INSP) jumped 3%. Is now the time to buy Inspire Medical Systems? Access our full analysis report here, it's free. Drug Development Inputs & Services company UFP Technologies (NASDAQ:UFPT) jumped 3.5%. Is now the time to buy UFP Technologies? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Globus Medical (NYSE:GMED) jumped 3%. Is now the time to buy Globus Medical? Access our full analysis report here, it's free. Medical Devices & Supplies - Diversified company Neogen (NASDAQ:NEOG) jumped 3.4%. Is now the time to buy Neogen? Access our full analysis report here, it's free. Dental Equipment & Technology company Dentsply Sirona (NASDAQ:XRAY) jumped 3.1%. Is now the time to buy Dentsply Sirona? Access our full analysis report here, it's free. Zooming In On UFP Technologies (UFPT) UFP Technologies's shares are very volatile and have had 24 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 7 days ago when the stock gained 11.9% on the news that the company posted record second-quarter results and beat analyst profit expectations. The medical products company reported a 37.2% surge in sales to $151.2 million compared to the same period last year. Its adjusted earnings per share reached $2.50, which surpassed Wall Street's consensus estimate of $2.25. This strong performance was primarily driven by a 46% jump in its MedTech business, fueled by demand in areas like robotic-assisted surgery. However, the results included a 20% decline in its Advanced Components division, and the company noted increased labor costs pressured margins. UFP Technologies is down 10.2% since the beginning of the year, and at $221.03 per share, it is trading 38.3% below its 52-week high of $358.42 from September 2024. Investors who bought $1,000 worth of UFP Technologies's shares 5 years ago would now be looking at an investment worth $5,057. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
20 minutes ago
- Yahoo
Moderna, Teleflex, Envista, Enovis, and UnitedHealth Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Therapeutics company Moderna (NASDAQ:MRNA) jumped 3.1%. Is now the time to buy Moderna? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company Teleflex (NYSE:TFX) jumped 4.1%. Is now the time to buy Teleflex? Access our full analysis report here, it's free. Dental Equipment & Technology company Envista (NYSE:NVST) jumped 3.1%. Is now the time to buy Envista? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Enovis (NYSE:ENOV) jumped 3.5%. Is now the time to buy Enovis? Access our full analysis report here, it's free. Health Insurance Providers company UnitedHealth (NYSE:UNH) jumped 3%. Is now the time to buy UnitedHealth? Access our full analysis report here, it's free. Zooming In On Teleflex (TFX) Teleflex's shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 6 months ago when the stock dropped 22.9% on the news that the company reported disappointing fourth-quarter results, with revenue missing expectations by a significant margin. On a constant currency basis, revenue increased 3.2%, but this still fell short of Wall Street's estimates. Weak demand in Interventional Urology wiped out gains in the Interventional and Surgical units. Looking ahead, the company's 2025 revenue guidance implies little to no growth, with management projecting revenue to be flat to slightly up. Overall, this was a weaker quarter, weighed down by sluggish growth, margin pressures, and a subdued outlook. Teleflex is down 32.8% since the beginning of the year, and at $120.33 per share, it is trading 51.3% below its 52-week high of $247.32 from September 2024. Investors who bought $1,000 worth of Teleflex's shares 5 years ago would now be looking at an investment worth $320.02. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
20 minutes ago
- Yahoo
Expedia Group Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore Expedia Group's Fair Values from the Community and select yours Expedia Group (NASDAQ:EXPE) Second Quarter 2025 Results Key Financial Results Revenue: US$3.79b (up 6.4% from 2Q 2024). Net income: US$330.0m (down 14% from 2Q 2024). Profit margin: 8.7% (down from 11% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: US$2.61 (down from US$2.93 in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Expedia Group Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 25%. Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Hospitality industry in the US. Performance of the American Hospitality industry. The company's shares are up 4.1% from a week ago. Balance Sheet Analysis While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Expedia Group's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
